Cadrenal Therapeutics, Inc. (CVKD): R&D Expense
$4.10M
Year ended 2025-12-31
$2.83M
Trailing 12 months to 2026-06-30
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $4.10M | -2.5% | 2026-03-31, From 2025-01-01 |
| 2024-12-31 | $4.21M | +3.0% | 2026-03-31, From 2024-01-01 |
| 2023-12-31 | $4.08M | n/a | 2025-03-13, From 2023-01-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Cadrenal Therapeutics, Inc. (CVKD) | 2025-12-31 | $4.10M | -2.5% |
| Lexaria Bioscience Corp. (LEXX) | 2025-08-31 | $8.24M | +249.0% |
| Pulmatrix, Inc. (PULM) | 2025-12-31 | $38.0K | -99.5% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $684.0K | +4.1% |
| Bio-Path Holdings, Inc. (BPTH) | 2024-12-31 | $7.29M | -37.2% |
| Azitra, Inc. (AZTR) | 2025-12-31 | $4.84M | +2.4% |
| Enveric Biosciences, Inc. (ENVB) | 2025-12-31 | $2.78M | -2.1% |
| Protagenic Therapeutics, Inc.\new (PTIX) | 2026-03-31 | $901.9K | +139.4% |
| Petros Pharmaceuticals, Inc. (PTPI) | 2024-12-31 | $2.62M | +8.5% |
Compare CVKD, LEXX, PULM, ISCO side by side · Screen every company in Pharmaceutical Preparations ↗